Podcasts about acetaminophen

In this episode, Dr. Kaur and Dr. Abhishek join us to discuss their recent study on acetaminophen, exploring how it compares to NSAIDs in safety and effectiveness. They break down their use of the Clinical Practice Research Datalink (CPRD), key findings—especially in arthritis patients—and what this means for clinical practice. It's an insightful look at how big data can challenge assumptions about one of the most used pain medications. 

Okay, so what should we know when picking an over the counter medication?? Dr. Ratzloff, Sanford Health, helps break down everything you should know about picking an over the counter medication. Because, you know we all have one we think is best... See omnystudio.com/listener for privacy information.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! New ACP Guidelines Recommend Adding Triptan to NSAID or Acetaminophen for Migraines The American College of Physicians now recommends adding a triptan to NSAIDs or acetaminophen for moderate to severe acute migraines and urges clinicians to initiate combination therapy early. Automated Insulin Delivery Effectively Lowers HbA1c in Type 2 Diabetes  Tandem Diabetes Care's Control-IQ+ automated insulin delivery system led to greater HbA1c reduction than continuous glucose monitoring alone in adults with insulin-requiring type 2 diabetes. FDA Approves Guselkumab (Tremfya) For Crohn's Disease  The FDA approved guselkumab for moderately to severely active Crohn's disease based on phase 3 trial data demonstrating superior efficacy over ustekinumab on endoscopic endpoints. FDA Approves Oral Iptacopan (Fabhalta) as First C3 Glomerulopathy Therapy  The FDA approved iptacopan as the first therapy for C3 glomerulopathy, with phase 3 data showing significant proteinuria reduction and sustained efficacy at 12 months. FDA Approves Vutrisiran (AMVUTTRA) for ATTR-CM  The FDA expanded vutrisiran's approval for cardiomyopathy in transthyretin-mediated amyloidosis, making it the first RNAi therapeutic to reduce cardiovascular mortality and hospitalizations in ATTR-CM.

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠Acetaminophen⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the MSK section.Follow⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

00:00 Show open/ Mioshi Moses, VP- AARP volunteer programs, on free tax help for Central Ohioans 5:27 Dr. Kathleen Wilson on Acetaminophen use during cold and flu season 11:44 Amy Goodson, Registered Dietician, on the benefits of a high-protein diet. 18:30 Face the State: Ohio's gubernatorial race; Vivek Ramaswamy in New Albany; other candidates' reactions to Ramaswamy entering race; marijuana bill passes state Senate; a new bill regarding cryptocurrency in Ohio; a bill that would eliminate police quotas; a state transportation budget proposal; new legislation regarding Ohio's schools. 27:04 Face the State: Legislation regarding prostitution. The Ohio Legislative Black Caucus with State Senator Hearcel Craig (D- Columbus) and State Representative Dontavius Jarrells (D- Columbus).

Clinical research studies incorporating supplemental oral enzymes report significant reductions in stomach pain after eating, fullness, bloating and nausea. And don't miss the following topics that Terry will also discuss on this show: Drink a Soda and Lose 12 Minutes of Your Life Best-Selling Drugs in 2024 Kids with Kidney Stones Coffee and Tea Reduce Cancer Risk Hidden Risks of Acetaminophen

Send us a textAnesthesiologist Dr. Todd Bertoch speaks with Dr. Michael Koren in this exciting episode about the a new pain medication, Journavx (suzetrigine), which was just approved by the FDA in January, 2025. The doctors discuss this breakthrough pain management medication, its safety profile, side effects, and how it compares to NSAIDs, acetaminophen, and opioids. They also dive into the approval process, how trials were conducted and standardized, and where the medication will go from here.Koren's Key Takeaways:New options like suzetrigine for pain medication that are non-addicting are neededThis medication is another tool, not a replacement for opioidsThe clinical trials for this medication have been rigorousBe a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on AppleWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textDr. Hernan A. Bazan MD, FACS, CEO & Co-Founder of South Rampart Pharma, Inc. ( https://southrampartpharma.com/about-us/hernan-bazan/ ), a clinical stage biopharma company developing safer, non-opioid therapies for acute and chronic pain, where he spearheads the company's scientific, clinical and technology development efforts, as well as it's fundraising. As an academic vascular surgeon, Dr. Bazan is the John Ochsner Endowed Professor of Surgery in Innovation ( https://www.ochsner.org/doctors/hernan-bazan ). His clinical interests include treating carotid artery disease and acute stroke, using minimally invasive approaches to aortic aneurysms and peripheral arterial disease, and managing acute post-operative pain. Over the years, Dr. Bazan has realized the significant clinical and societal need for safer and non-addictive pain relief in ambulatory and post-operative settings. From these critical unmet needs, South Rampart Pharma, Inc. was founded in 2016 to develop safer, non-opioid therapies for acute and chronic pain.Dr. Bazan authored the first manuscript describing the library of analgesic compounds' synthesis, lack of hepatoxicity analgesic characterization, and antipyretic properties, published in September 2020 in the European Journal of Medicinal Chemistry and a current paper under advanced review (open access) in Nature Communications.Dr. Bazan is the PI or Co-I on two NIH/NINDS STTR (small business commercialization) grants to develop a novel non-narcotic and non-toxic analgesic to safely treat acute, chronic, and neuropathic pain. He is the co-inventor of 7 issued or pending patents and has authored over 50 publications. He and his team have completed Phase 1 clinical trials, paving the way for Phase 2 RCTs in acute and neuropathic pain. He was bestowed the 2024 NIH HEAL Director's Trailblazer Award for this work.Dr. Bazan received a B.S. in Molecular Biology (Vanderbilt University). He spent two years in medical school as a Howard Hughes Medical Institute (HHMI) Research Scholar at the NIH. He earned an M.D. (Georgetown University), followed by a General Surgery Residency (Mt. Sinai Hospital, New York) and a Vascular Surgery Fellowship (Yale University).#Pain #Opioids #NSAIDS #Acetaminophen #Analgesia #Nociception #PostOperative #HernanBazan #NicolasBazan #SouthRampartPharma #Ochsner #Fentanyl #Aspirin #Ibuprofen   #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Nearly all pain relievers on the market use the phrase “for fast, temporary relief.” Aspirin, Ibuprofen, Acetaminophen – they’ll give a little relief, for a little while. But when it comes to forgiveness of our sin, we’re more interest in “immediate, everlasting relief” from our guilt and guile. Today on A NEW BEGINNING, as Pastor Greg Laurie takes us to the story of the first Passover, we’ll see God provided a solution for sin that forever paid the price that had to be paid. Send help and hope to SoCal Listen on harvest.org --- Learn more and subscribe to Harvest updates at harvest.org A New Beginning is the daily half-hour program hosted by Greg Laurie, pastor of Harvest Christian Fellowship in Southern California. For over 30 years, Pastor Greg and Harvest Ministries have endeavored to know God and make Him known through media and large-scale evangelism. This podcast is supported by the generosity of our Harvest Partners.Support the show: https://harvest.org/supportSee omnystudio.com/listener for privacy information.

Nearly all pain relievers on the market use the phrase “for fast, temporary relief.” Aspirin, Ibuprofen, Acetaminophen – they’ll give a little relief, for a little while. But when it comes to forgiveness of our sin, we’re more interest in “immediate, everlasting relief” from our guilt and guile. Today on A NEW BEGINNING, as Pastor Greg Laurie takes us to the story of the first Passover, we’ll see God provided a solution for sin that forever paid the price that had to be paid. Send help and hope to SoCal Listen on harvest.org --- Learn more and subscribe to Harvest updates at harvest.org A New Beginning is the daily half-hour program hosted by Greg Laurie, pastor of Harvest Christian Fellowship in Southern California. For over 30 years, Pastor Greg and Harvest Ministries have endeavored to know God and make Him known through media and large-scale evangelism. This podcast is supported by the generosity of our Harvest Partners.Support the show: https://harvest.org/supportSee omnystudio.com/listener for privacy information.

Show notes at pharmacyjoe.com/episode984. In this episode, I'll discuss N-acetylcysteine in non-acetaminophen-induced acute liver failure. The post 984: N-acetylcysteine in Acute Liver Failure Not Caused by Acetaminophen appeared first on Pharmacy Joe.

In this episode, we review the high-yield topic ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Acetaminophen Overdose⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠from the Drugs section at ⁠⁠⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠ Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Here's another great podcast from early '24. This was a great conversation and finished the year at #9. In this podcast episode, Winston and I delve into the intricate world of pain and its pathways. They explore the nervous system's role in pain transmission, the different types of pain including nociceptive, neuropathic, and nociplastic pain, and the significance of sensitization in chronic pain conditions. The discussion also highlights practical approaches to pain management, including the use of multimodal therapies and the impact of neuroplasticity on pain perception, particularly in cases like phantom limb pain. In this conversation, Dennis discusses the complexities of pain management, emphasizing the importance of understanding the patient's history and the trajectory of their pain. He highlights the shift from opioid reliance to a multimodal approach that includes various analgesics such as acetaminophen, NSAIDs, lidocaine, capsaicin, cannabinoids, and ketamine. Dennis also covers the role of anticonvulsants and antidepressants in managing chronic pain, providing practical recommendations for healthcare practitioners. Takeaways Understanding pain pathways can enhance treatment effectiveness. Pain transmission involves complex processes in the nervous system. There are three main types of pain: nociceptive, neuropathic, and nociplastic. Peripheral and central sensitization play crucial roles in chronic pain. Ketamine is effective in reducing central sensitization. The placebo effect can significantly influence pain management. Recognizing nociplastic pain is essential for proper treatment. Mirror therapy can help alleviate phantom limb pain. Neuroplasticity affects how pain is perceived and treated. A multimodal approach is necessary for effective pain management. History taking is crucial in understanding pain types. The goal of pain management is to improve function and quality of life. Acetaminophen can be as effective as opioids in certain cases. Lidocaine should be used with caution due to potential side effects. Capsaicin is a natural option for neuropathic pain relief. Opioids have significant side effects and should be used carefully. Cannabinoids are gaining popularity but require more research. Ketamine offers a new avenue for pain management. Anticonvulsants can help with neuropathic pain but take time to work. Amitriptyline is a cost-effective option for chronic pain management. Thank you to Delta Development Team for in part, sponsoring this podcast. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠deltadevteam.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ For more content go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠ Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care

Acetaminophen (Paracetamol) is a common over-the-counter medication that has gained substantial media attention regarding its use by pregnant women. Although estimates vary considerably, most studies and surveys report that around 40–65% of women take acetaminophen sometime during their pregnancy. Historically considered safe, concern was initially raised back in 2014 with a JAMA Pediatrics publication stated that use in pregnancy lead to ADHD in the offspring. Seven years later, in 2021, a consensus statement published in Nature Reviews Endocrinology suggested that acetaminophen use in pregnancy might increase the risk of neurodevelopmental and urogenital tract abnormalities in offspring and called for “precautionary action”. This lead tgo an ACOG response back in Sep 29, 2021 (we will review). This is very controversial. Today, Dec 5, 2024, a new clinical perspective was published in Obstetrics & Gynecology adding another flavor to the mix. Is acetaminophen a direct cause of fetal harm? Listen in for details!

We sit down with one of our toxicologists to discuss acetaminophen toxicity. Hosts: Marlis Gnirke, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Acetaminophen_Toxicity.mp3 Download One Comment Tags: Toxicology Show Notes Table of Contents 0:35 – Hidden acetaminophen toxicity in OTC products 3:24 – Pharmacokinetics and toxicokinetics  6:06 – Clinical Course 9:22 – The antidote – NAC 11:02 – The Rumack-Matthew Nomogram  17:36 – Treatment protocols 22:34 – Monitoring and Lab Work 23:23 – Considerations when treating pediatric patients 23:57 – IV APAP overdose, fomepizole  25:42 – Take Home Points Acetaminophen vs. Tylenol: The importance of recognizing that acetaminophen is found in many products beyond Tylenol. Common medications containing acetaminophen, such as Excedrin, Fioricet, Percocet, Dayquil/Nyquil, and others. The risk of unintentional overdose due to combination products. Prevalence of Acetaminophen Toxicity:

Megan Edwards, PharmD discusses optimal management of acetaminophen overdose.   For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.  You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

Clindamycin is an antibiotic for infection. It inhibits protein synthesis by binding to the 50s ribosomal subunit and is well known to contribute to C. Diff. risk. Acetaminophen is a common over-the-counter medication that relieves pain and fever. It does not have much benefit in reducing inflammation, however. Ferrous sulfate is a supplement that can be useful in treating anemia. Dark stools and constipation are two common adverse effects. Eletriptan is a medication used to abort migraine headaches. It has serotonin action. I discuss the potential for interactions with other serotonergic medications. Methocarbamol is an older skeletal muscle relaxant that makes an appearance on the Beers list as it can cause sedation, confusion, and increase the risk of falls.

部落格圖文版 https://linshibi.com/?p=46969 更多藥物解說 https://linshibi.com/?cat=4347 許多朋友都說日本版比台灣版有效，但其中是否有台灣視為管制藥品的成分？到底可不可以從日本帶回呢？ 日本大正百保能黃金A微粒（大正製藥パブロンゴールドA微粒） PABRON GOLD A〈GRANULES〉 1.這是複方的感冒藥物，其成份可舒緩感冒可能有的各種症狀（咳嗽、痰、喉嚨痛、打噴嚏、流鼻水、鼻塞、畏寒、發燒、頭痛、關節疼痛、肌肉痠痛） 。 2.主要有七種成分：1包（0.96g）中含有 Acetaminophen（乙醯胺酚）300mg：大家很熟悉的普拿疼，解熱鎮痛用。 Dihydrocodeine Phosphate（磷酸二氫可待因）8mg：鎮咳劑。 Guaifenesin（癒創木酚甘油醚） 60mg：袪痰劑 dl-Methylephedrine Hydrochloride（鹽酸甲基麻黃鹼）20mg：支氣管擴張(鎮咳)。 Chlorpheniramine Maleate（縮水蘋果酸氯芬尼拉明）2.5mg：抗組織胺，治鼻塞、鼻涕 Anhydrous caffeine（無水咖啡因）25mg：止痛藥EVE中也有。 Riboflavin (vitamin B2)（核黃素）4mg：維他命B2。 3.台灣版的大正百保能感冒顆粒則是1包（1.2g），有八種成分。主要不同的地方有： a.鎮咳劑改為Dextromethorphan hbr（右美沙芬）15mg。 二氫可待因是屬於類鴉片（opioid）藥物，在台灣屬於管制藥品，要由醫師開立處方，一般藥局無法取得，因此替換為較沒有成癮問題的右美沙芬。 b.抗組胺有改變。不過兩者都是第一代抗組胺，同樣都可能有嗜睡的副作用。因此仿單中有寫服用後請勿駕駛操作交通工具或機械類。 c.鹽酸甲基麻黃鹼從20mg降為10mg。我想是因為這類藥物可為製造安非他命類毒品之毒品先驅原料，因此故意降低其劑量。 d.多增加了Thiamine mononitrate維他命B1 8mg。 04b解讀： 1.感冒是病毒造成的上呼吸道感染的俗稱，可以有非常多症狀。病人來就醫時，醫師會依據您有什麼症狀針對性的給予單方藥物。所以我個人是不太建議大家使用這樣的複方大雜燴藥物，因為你可能會吃到不需要吃的藥物，而承受不必要的風險。 2.比方說如果你主要是發燒喉嚨痛，其他症狀都不明顯，你需要的是解熱鎮痛的藥物，而不是大正百保能。因為他解熱鎮痛的成分是最普通的乙醯胺酚罷了，沒有太大的效用！你可能還不如使用EVE效果會好些。 3.就成分上來看，日版顯然在止咳上效果會較佳，但風險是嗜睡的副作用有可能較明顯。另外主要就是在台灣屬於管制藥品的二氫可待因，可能會有噁心、嘔吐、便秘、鎮靜、嗜睡、皮膚癢等副作用，並隨劑量上升而增加。長期使用更可能產生成癮性，高劑量會有呼吸抑制風險。 4.另外一個日本很常見的新LuLuA感冒藥也同樣含有二氫可待因。日本近年在年輕族群出現了購買市售感冒藥物濫用的情形，因此各位常常到日本藥妝店目前會遇到每人限購一盒的狀況，這個之前已經和大家分享過了。 5.至於到底能不能帶回台灣？我的理解是侷限於自用，可以。而現在藥妝店普遍都有限購，我其實也沒有太擔心大家會帶太多。只是如果你帶的量會讓海關懷疑這超過了自用的量，可能會引起關注。 最後是老話一句：不要迷信日本成藥，不要把它當土產買來送人！ 更多藥物解說 https://linshibi.com/?cat=4347

Acetaminophen overdose is one of the most common medication concerns we see in the ED. It is important to know when to be concerned and when to treat as true overdoses can cause liver failure and death. UC Davis medical toxicologist, Dr. Hoan Nguyen, joins us in this episode to discuss a new consensus statement published in JAMA Network Open in August 2023: Managing of Acetaminophen Poisoning in the US and Canada. We discuss the updated approach and walk through as hypothetical case. At the end of this episode, you'll be able to identify high risk patients, know what labs to draw, when to start NAC, transfer, and call your local toxicologist. Do these updated guidelines change your practice? Hit us up on social media @empulsepodcast or at ucdavisem.com Hosts: Dr. Julia Magaña, Professor of Pediatric Emergency Medicine at UC Davis Dr. Sarah Medeiros, Associate Professor of Emergency Medicine at UC Davis Guests: Dr. HoanVu Nguyen, Military Emergency Physician and Medical Toxicologist at UC Davis.  Resources: Dart RC, Mullins ME, Matoushek T, et al. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. JAMA Netw Open. 2023 Aug 1;6(8):e2327739. doi: 10.1001/jamanetworkopen.2023.27739. Erratum in: JAMA Netw Open. 2023 Sep 5;6(9):e2337926. doi: 10.1001/jamanetworkopen.2023.37926. PMID: 37552484. ***** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services.

Acetaminophen is widely available over the counter in the United States, increasing the risk of overdose (both acute and chronic). Several factors contribute to the complexity of managing this tricky condition in the emergency department, but until recently, there has been no true standardized approach. Guidance issued in 2023 aims to establish a helpful framework for managing acetaminophen overdose.  EMRA*Cast host Kyle Duke, MD, breaks it down with EMRA Toxicology Committee Chair Mason Jackson, MD.

Neste episódio do Journal Club, as apresentadoras Mariana e Marôla mergulham em vários estudos impactantes em neonatologia. Elas apresentam uma série de artigos sobre o tratamento do canal arterial patente (PCA), discutindo tratamentos farmacológicos, técnicas de fechamento transcateter e novas diretrizes de prática clínica. A conversa destaca o cenário em evolução do tratamento do PCA e a necessidade de pesquisas mais robustas, para que esse assunto deixe de ser a eterna polêmica da semana em neonatologia.Ao longo do episódio, Mariana e Marôla fornecem comentários perspicazes sobre as implicações clínicas desses estudos, tornando pesquisas complexas acessíveis aos ouvintes e, ao mesmo tempo, enfatizando a necessidade de investigação contínua em áreas-chave do atendimento neonatal. Os artigos abordados no episódio de hoje do podcast podem ser encontrados aqui:1. Acetaminophen for Patent Ductus Arteriosus and Risk of Mortality and Pulmonary MorbidityJensen EA, DeMauro SB, Rysavy MA, Patel RM, Laughon MM, Eichenwald EC, Do BT, Das A, Wright CJ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Pediatrics. 2024 Jul 16:e2023065056. https://pubmed.ncbi.nlm.nih.gov/39011550/#:~:text=Acetaminophen%20was%20associated%20with%20increased,%25%20CI%200.91%2D1.82).2. Transcatheter and Surgical Ductus Arteriosus Closure in Very Low Birth Weight Infants: 2018-2022.Leahy BF, Edwards EM, Ehret DEY, Soll RF, Yeager SB, Flyer JN.Pediatrics. 2024 Jul 15:e2024065905. https://pubmed.ncbi.nlm.nih.gov/39005106/#:~:text=Transcatheter%20closure%20increased%20from%2029.8,0.94%3B%200.89%2D1.01).3. Long term follow-up of patients with patent ductus arteriosus after transcatheter closure.Peng Y, Cheng Z, Zhang Y, Yi Q.Pediatr Res. 2024 Jun 14. doi: 10.1038/s41390-024-03317-x. Online ahead of print.PMID: 38877281 https://pubmed.ncbi.nlm.nih.gov/38877281/4. Procedural closure of the patent ductus arteriosus in preterm infants: a clinical practice guideline.Mitra, S., Bischoff, A.R., Sathanandam, S. et al. Procedural closure of the patent ductus arteriosus in preterm infants: a clinical practice guideline. J Perinatol (2024). https://doi.org/10.1038/s41372-024-02052-9https://www.nature.com/articles/s41372-024-02052-9#:~:text=Overall%2C%20the%20panel%20felt%20that,persistent%20large%20transductal%20shunt%20on Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Se estiver gostando do nosso Podcast, por favor deixe sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

Learn how pyroglutamic acidosis can occur with therapeutic acetaminophen administration in at-risk pediatric patients, resulting in high anion gap metabolic acidosis. For more on nephrology, visit here. 

Send us a Text Message.Acetaminophen for Patent Ductus Arteriosus and Risk of Mortality and Pulmonary Morbidity.Jensen EA, DeMauro SB, Rysavy MA, Patel RM, Laughon MM, Eichenwald EC, Do BT, Das A, Wright CJ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Pediatrics. 2024 Jul 16:e2023065056. doi: 10.1542/peds.2023-065056. Online ahead of print.PMID: 39011550As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Acetaminophen use is universally promoted as safe for adults and children alike, but the use of acetaminophen in babies and young children may be strongly associated with autism, perhaps because of well-known deficiencies in the metabolic breakdown of pharmaceuticals during early development. One explanation for the increased prevalence of autism is that increased exposure to acetaminophen, exacerbated by inflammation and oxidative stress, is neurotoxic in babies and small children. Dr. William Parker has studied the effects of acetaminophen use in infants and children for decades, and today he presents his research. Please join us for an absolutely eye-opening conversation about the dangers of acetaminophen, and stay tuned as Kay and Elanie cover natural, risk-free alternatives to its use. Dr. William and his team have put together a webpage tailored for moms, designed to help them understand the research: https://www.wplaboratory.org/tips-for-parents-and-caregivers Dr. William Parker's research is published and can be found here: https://pubmed.ncbi.nlm.nih.gov/28415925/ Parker, William et al. “The role of oxidative stress, inflammation and acetaminophen exposure from birth to early childhood in the induction of autism.” The Journal of international medical research vol. 45,2 (2017): 407-438. doi:10.1177/0300060517693423 --- Support this podcast: https://podcasters.spotify.com/pod/show/elanie-welch/support

In a clinical study of 100 people with dry eyes, 4 capsules daily of sea buckthorn significantly relieved dry eye symptoms, including redness and burning! Don't miss these other topics that Terry will discuss on this show: Low T (Testosterone) What is the difference between Ibuprofen and Acetaminophen? Is a Broken Hip Worse than Cancer? A Closer Look at: LDL Cholesterol

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Consider the humble rock (or: why the dumb thing kills you), published by pleiotroth on July 5, 2024 on LessWrong. When people think about street-fights and what they should do when they find themselves in the unfortunate position of being in one, they tend to stumble across a pretty concerning thought relatively early on: "What if my attacker has a knife?" . Then they will put loads of cognitive effort into strategies for how to deal with attackers wielding blades. On first glance this makes sense. Knives aren't that uncommon and they are very scary, so it feels pretty dignified to have prepared for such scenarios (I apologize if this anecdote is horribly unrelatable to Statesians). The issue is that -all in all- knife related injuries from brawls or random attacks aren't that common in most settings. Weapons of opportunity (a rock, a brick, a bottle, some piece of metal, anything you can pick up in the moment) are much more common. They are less scary, but everyone has access to them and I've met few people without experience who come up with plans for defending against those before they start thinking about knives. It's not the really scary thing that kills you. It's the minimum viable thing. When deliberating poisons, people tend to think of the flashy, potent ones. Cyanide, Strychnine, Tetrodotoxin. Anything sufficiently scary with LDs in the low milligrams. The ones that are difficult to defend against and known first and foremost for their toxicity. On first pass this seems reasonable, but the fact that they are scary and hard to defend against means that it is very rare to encounter them. It is staggeringly more likely that you will suffer poisoning from Acetaminophen or the likes. OTC medications, cleaning products, batteries, pesticides, supplements. Poisons which are weak enough to be common. It's not the really scary thing that kills you. It's the minimum viable thing. My impression is that people in AI safety circles follow a similar pattern of directing most of their attention at the very competent, very scary parts of risk-space, rather than the large parts. Unless I am missing something, it feels pretty clear that the majority of doom-worlds are ones in which we die stupidly. Not by the deft hands of some superintelligent optimizer tiling the universe with its will, but the clumsy ones of a process that is powerful enough to kill a significant chunk of humanity but not smart enough to do anything impressive after that point. Not a schemer but an unstable idiot placed a little too close to a very spooky button by other unstable idiots. Killing enough of humanity that the rest will die soon after isn't that hard. We are very very fragile. Of course the sorts of scenarios which kill everyone immediately are less likely in worlds where there isn't competent, directed effort, but the post-apocalypse is a dangerous place and the odds that the people equipped to rebuild civilisation will be among the survivors, find themselves around the means to do so, make a few more lucky rolls on location and keep that spark going down a number of generations are low. Nowhere near zero but low. In bits of branch-space in which it is technically possible to bounce back given some factors, lots of timelines get shredded. You don't need a lot of general intelligence to design a bio-weapon or cause the leak of one. With militaries increasingly happy to hand weapons to black-boxes, you don't need to be very clever to start a nuclear incident. The meme which makes humanity destroy itself too might be relatively simple. In most worlds, before you get competent maximizers with the kind of goal content integrity, embedded agency and all the rest to kill humanity deliberately, keep the lights on afterwards and have a plan for what to do next, you get a truly baffling number of fla...

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-384 Overview: This episode investigates the inaccurate correlation made between acetaminophen use during pregnancy and an increased risk of developmental disorders, including autism spectrum disorder, in children. Expert faculty discuss the history of these claims, followed by a study evaluating outcomes in children, and emphasize the importance of evidence-based decision-making for patients and clinicians. Episode resource links: Ahlqvist VH, Sjöqvist H, Dalman C, et al. Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability. JAMA. 2024;331(14):1205–1214. doi:10.1001/jama.2024.3172 Nat Rev Endocrinol. 2021 Dec;17(12):757-766. doi: 10.1038/s41574-021-00553-7 Guest: Aylin Madore, MD, MEd   Music Credit: Richard Onorato

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-384 Overview: This episode investigates the inaccurate correlation made between acetaminophen use during pregnancy and an increased risk of developmental disorders, including autism spectrum disorder, in children. Expert faculty discuss the history of these claims, followed by a study evaluating outcomes in children, and emphasize the importance of evidence-based decision-making for patients and clinicians. Episode resource links: Ahlqvist VH, Sjöqvist H, Dalman C, et al. Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability. JAMA. 2024;331(14):1205–1214. doi:10.1001/jama.2024.3172 Nat Rev Endocrinol. 2021 Dec;17(12):757-766. doi: 10.1038/s41574-021-00553-7 Guest: Aylin Madore, MD, MEd   Music Credit: Richard Onorato

While modern medicine is definitely a wonder, it isn't always working to help your body. Chronic use of medicines like ibuprofen (Advil), acetaminophen (Tylenol), and proton pump inhibitors (Prilosec, Nexium, Prevacid, etc.) come with some nasty side effects that you might not know about. Inside this episode, you'll discover the potentially negative consequences of popping these pills daily, as well as what you can do to maximize your body's function and health without them -- pain-free! --- Show Notes: Your Daily Ibuprofen is Wrecking Your Gut! Tylenol SUCKS For Your Liver Pharmacology of Proton Pump Inhibitors Review of the Long-Term Effects of Proton Pump Inhibitors Proton pump inhibitors and dementia: A nationwide population-based study Join my pH Balance DIY Program - and get off the PPIs for good! --- Join the Compass Method DIY Program Jump inside my Rock the Bloat Minicourse Get my Core-Gi Workout Program with the exclusive listener discount! Join my Brain Rewiring Masterclass You can learn more about me by following on IG @imperfectlypaigewellness or by checking out my blog, freebies, and offers on my website: https://imperfectlypaigewellness.com Please share with #PaigeTalksWellness to help get the word out about the show - and join the Imperfect Health Fam over on Facebook.

Does prenatal acetaminophen exposure increase risk for neurodevelopmental disorders? Find out about this and more in today's PeerDirect Medical News Podcast.

In 2014, a publication out of JAMA Pediatrics raised questions regarding the safety of acetaminophen in pregnancy describing a possible “association” with later neurodevelopmental and cognitive delays in children. What followed was a string of controversial publications (observational) with mounds of conflicting data. This led to a controversial international consensus opinion in 2021 calling for “caution for use” regarding acetaminophen in pregnancy. The ACOG had a strong rebuttal to that statement at that time. But now, as of April 9, 2024, we have new data on acetaminophen/paracetamol use in pregnancy and possible neurodevelopmental affects in children. This new study was published out of JAMA network and followed 2.4 million children with sibling pairs out of Sweden. This is making a lot of news within the last 24 hours and it is hot off the press

Editor's Summary by Kristin Walter, MD, MS, Deputy Editor of JAMA, the Journal of the American Medical Association, for the April 9, 2024, issue.

Dive into the realm of advanced pain management with Dr. Mark Epstein, as he unveils the latest on Tramadol, Gabapentinoids, and more in our dedicated pain management series. Quick Summary: This episode, part of a five-episode series from a comprehensive workshop held in late 2023, focuses on Tramadol, Gabapentinoids, and their roles in veterinary pain management. Dr. Mark Epstein, a renowned expert, discusses the effectiveness, applications, and considerations of these medications in dogs and cats, offering practitioners insights to enhance patient care. Speaker: Dr. Mark Epstein, DVM, DABVP, CVPP, a leading authority in veterinary pain management, shares his expertise. Dr. Epstein is the medical director at Total Bond Veterinary Hospitals, North Carolina, and a celebrated figure in the field, having led significant pain management guideline programs. Main Talking Points: Tramadol's Efficacy: Exploration of Tramadol's varying effectiveness in dogs versus cats, highlighting its limitations and potential uses. Gabapentinoids: Discussion on Gabapentin and Pregabalin's roles in treating neuropathic pain, with specific dosing insights for both species. Emerging Therapies: Introduction to promising medications like Amantadine and Acetaminophen, outlining their contributions to multi-modal pain management strategies. Interesting Quotes: "The conversations about Tramadol... pretty much settled by now that the oral form of it in dogs is simply no strong evidence that it's effective." - Dr. Epstein "When it comes to dogs... we need more evidence to show it. So this is like going to be a therapeutic in progress of its study." - Dr. Epstein on Tapentadol "We can say with some confidence that [Gabapentinoids] can have a benefit when there's a neuropathic component to pain." - Dr. Epstein Timestamps: 0:00 - Introduction  2:05 - Tramadol's efficacy and limitations 5:40 - Gabapentinoids in pain management 10:25 - Insights into Amantadine and Acetaminophen 11:00 - Final thoughts   Visit IVDI.org to learn more about the Veterinary Dental Practitioner Program. Tune in next week for more insights into veterinary dentistry and pain management.   This episode provides a deep dive into the complexities of using Tramadol and Gabapentinoids for managing pain in veterinary patients, guided by Dr. Mark Epstein's rich experience and research. By dissecting the latest findings and practical considerations, veterinarians and technicians can glean valuable strategies for optimizing pain management in their practice. Affiliate & Sponsor Links: This series is brought to you by the International Veterinary Dentistry Institute (IVDI.org), offering comprehensive training to elevate your veterinary dentistry skills.

有了對EVE還有LOXONIN的基本知識，就很容易理解BUFFERIN系列了喔。其實日本這些解熱鎮痛的成藥邏輯都滿像的。BUFFERIN系列主成分就是阿斯匹靈，布洛芬還有普拿疼的組合。 EVE A系列止痛藥解說 https://linshibi.com/?p=45191 1.BUFFERIN系列多數的主成分是和EVE是一樣的，就是布洛芬（ibuprofen），這裏就不重複介紹了。 2.阿斯匹靈（Aspirin，正式名稱是乙醯水楊酸，acetylsalicylic acid）則可說是第一個上市的NSAID。1899年，德國拜耳以阿斯匹靈為商標，將本品銷售至全球。 3.NSAID可抑制環氧合酶-1（COX-1）及環氧合酶-2（COX-2），進而減少前列腺素和血栓素的合成。抑制COX-2會有解熱鎮痛、抗發炎的效果，但抑制主要在胃部的COX-1會容易導致腸胃道出血和潰瘍。這是他產生副作用的機制。 4.阿斯匹靈對COX-1的抑制作用比對COX-2更強，因此對疼痛的緩解效果不如布洛芬，卻更容易引發胃腸道出血。近年醫師們多半不會把阿斯匹靈使用於解熱鎮痛，一些其他的場合才會使用他。比方說低劑量用以預防心血管疾病等。 5.普拿疼（這是俗名，正式名稱是乙醯胺酚，Acetaminophen）是非常廣泛用於第一線解熱鎮痛的藥物。他不是NSAID，主要通過抑制分布在中樞神經系統的COX-2，屬於輕度止痛藥，並無明顯抗發炎活性。效果雖沒有NSAID強，但使用起來相對安全，較沒有傷腎傷胃的考慮。兒童和孕婦可以使用。 6.六種BUFFERIN的比較：主要有BUFFERIN A，BUFFERIN PREMIUM，BUFFERIN PREMIUM DX，BUFFERIN Light，BUFFERIN Luna i，BUFFERIN Luna J。 （除了BUFFERIN PREMIUM外，都不含鎮靜成分。其中三種有咖啡因成份） BUFFERIN A 經典款，一劑中含有阿斯匹靈660毫克，最多一日兩回。添加制酸劑Hydrotalcite 200毫克，這也是在台灣大家很常使用的胃藥（常見名稱為Nacid）。雖然加了胃藥，但絕不能說這個藥就不會傷胃了，他可是阿斯匹靈呀！中文官網上寫"不刺激胃部"，我個人無法同意。 BUFFERIN PREMIUM 針對嚴重頭痛。一劑中含有布洛芬130毫克，乙醯胺酚130毫克。添加了和EVE A同樣的兩個成分：Anhydrous Caffeine（無水咖啡因） 80毫克和Allylisopropylacetylurea（丙烯異丙乙酸尿） 60毫克（以上劑量和EVE A一樣）。因此他的注意事項就和EVE A一樣了，會有鎮靜效果所以服用後不建議駕駛車輛或操作機械，且也有可能有血小板減少的副作用。添加了乾燥氫氧化鋁凝膠70毫克，可保護胃黏膜。一天最高建議可服用到三次，這樣布洛芬用量390毫克還是不會超過EVE建議的一天400~450毫克。 且做成容易服用的小顆粒藥錠，藥錠表面有塗層，容易服用。 BUFFERIN PREMIUM DX 針對嚴重頭痛。一劑中含有布洛芬160毫克，乙醯胺酚160毫克，無水咖啡因50毫克。拿掉了丙烯異丙乙酸尿，因此不含鎮靜成份。前兩者劑量調高，咖啡因劑量調低。同樣添加了乾燥氫氧化鋁凝膠70毫克，可保護胃黏膜。此外還有採用獨家技術的「Quick Attack錠」，號稱吸收和作用可以比較快。一天最高建議可服用到三次，這樣布洛芬用量480毫克，會稍稍超過EVE建議的一天400~450毫克。 BUFFERIN Light 相比於BUFFERIN A阿斯匹靈減量的版本。一劑中含有阿斯匹靈440毫克，乾燥氫氧化鋁凝膠200毫克。後者劑量有調高。因此官網寫效果溫和，顧慮到身體的配方。但如果很擔心傷胃，我個人是建議直接選PREMIUM比較實際。 BUFFERIN Luna i 針對生理痛。一劑中含有布洛芬130毫克，乙醯胺酚130毫克，無水咖啡因 80毫克。其實成份和BUFFERIN PREMIUM一樣，只是拿掉了丙烯異丙乙酸尿，因此不含鎮靜成份。同樣添加了乾燥氫氧化鋁凝膠70毫克，可保護胃黏膜。 BUFFERIN Luna J 針對小學，國中高中生的疼痛和發燒，這就是普拿疼啦，一劑含乙醯胺酚100毫克。上面那些藥15歲以下都不建議服用。號稱是沒有水也能服用的咀嚼錠，會在口中溶解，有水果味。七歲以下不建議使用，每個年齡的使用劑量建議不同，請看清楚再服用。 其實另外還有兩種針對3~7歲乙醯胺酚劑量更低的，小兒用BUFFERIN咀嚼錠還有小兒用BUFFERIN CⅡ是水果口味容易服用的退燒止痛藥。 注意事項 ： 1.BUFFERIN PREMIUM因為有丙烯異丙乙酸尿這個EVE A也有的鎮靜成分，服用後請勿駕駛或進行機械類的操作。且有造成血小板低下的風險，所以有相關疾病的人不建議服用。 2.BUFFERIN各種產品的成分不太相同，如果對其中一種過敏，可能要詳細比對可能是對哪個成份過敏，還有是多嚴重的過敏形式，才能判斷是否還可以使用其他類型的解熱鎮痛藥。 3.老話一句，身體如果有任何地方長期疼痛，應該要求助專業醫師，找出病因。特別是越來越壓不住的疼痛，很可能有什麼重要的潛在疾病，不要長期自己買藥吃，長期吃NSAID類止痛藥可能會傷胃造成胃潰瘍，也可能造成腎功能受損。 4.順道提醒大家，入境時單一藥品每人不得超過十二瓶。依照「入境旅客攜帶行李物品報驗稅放辦法」限量規定，非處方藥每種至多十二瓶（盒、罐、條、支），合計以不超過卅六瓶（盒、罐、條、支）為限。 歡迎追蹤林氏璧孔醫師的發聲管道，了解最新的日本旅遊訊息！ 我的電子名片 https://lit.link/linshibi 日本優惠券大平台和近期活動資訊 https://linshibi.com/?p=20443 日本藥妝店優惠券大集合 https://linshibi.com/?p=27381 歡迎贊助04b喝咖啡 https://pay.firstory.me/user/linshibi

TODAY ON THE ROBERT SCOTT BELL SHOW: Multimorbidity epidemic, Acetaminophen language delay, Parkinson's pesticides, Homeopathic Hit - Chimaphila Umbellata, Elderly antidepressants, Microwaved plastics, Food additive infertility, Toxic sewage fertilizer, Direct-to-consumer pharmaceutical advertising and MORE! https://robertscottbell.com/multimorbidity-epidemic-acetaminophen-language-delay-parkinsons-pesticides-homeopathic-hit-chimaphila-umbellata-elderly-antidepressants-microwaved-plastics-food-additive-infertility-toxic-s/

Combination intravenous formulation of acetaminophen and ibuprofen approved; recommendations from the ADA for dealing with acute dental pain; RSV vaccine under review for younger adult age group; Gilead call halt on investigational leukemia treatment hagrolimab; athlete foot spray recalled.

Bobbi rants about the "other" pain medications. Host: Dr. Bobbi Conner Producer: Topher Conlan

TODAY ON THE ROBERT SCOTT BELL SHOW: Healthcare student mandates, Ann Archer, Energy medicine, Balanced frequencies, Acetaminophen during Pregnancy, Uvulitis concerns, Fasting diet benefits, Kim Alexis, Aging gracefully, Clean lifestyle, Long COVID cognitive slowing, Homeopathic Hit – Manganum and MORE! http://www.robertscottbell.com/natural-remedies/healthcare-student-mandates-ann-archer-energy-medicine-balanced-frequencies-acetaminophen-during-pregnancy-uvulitis-concerns-fasting-diet-benefits-kim-alexis-aging-gracefully-clean-lifestyle/

This week's top international headlines, the Fighting Illini basketball takes on Purdue next week and a new study suggests that Acetaminophen is dangerous for children's language development. Stories by Stephanie Orellana, Peter Derrah, and Emily Huffman. Hosted by Ashley GilbertMusic by Boxout

In this episode, Ryan dives into cutting-edge research on the treatment of acetaminophen (APAP) overdose, featuring interviews with authors of several key abstracts from the North American Congress of Clinical Toxicology (NACCT) in Montreal Canada (Abstracts and posters available in the show notes). We get first looks insights into research evaluating the impact of fomepizole high risk acetaminophen overdose, as well as who gets fomepizole for acetaminophen overdose and dies. Then we evaluate the effectiveness of standard N-acetylcysteine (NAC) treatment in high risk patients and high dose NAC in high risk patients. Join us for an insightful discussion on these advancements that are reshaping the management of APAP toxicity. Guests include Dr. Masha Yemets PharmD, Dr. Molly Stott PharmD, Dr. Alexandru Ulici PharmD, and Dr. Michael Moss MD.   Link to published abstracts(First guest) Abstract #126 Characterizing fomepizole use in acetaminophen deaths reported to US poison centers- Dr. Yemets(Second guest) Abstract #125 Clinical impact of fomepizole as an adjunct therapy in massive acetaminophen overdose- Dr. Stott(Third guest) Abstract #131 Comparison of low-risk and high risk acetaminophen ingestions using the standard prescott protocol of intravenous N-acetylcysteine- Dr. Ulici(Fourth guest) Abstract #130 High-risk acetaminophen overdose outcomes after treatment with standard dose vs. increased dose N-acetylcysteine- Dr. MossOther studies discussed regarding NAC dosingATOM 2 Angela ChiewOutcomes of massive APAP treated with regular NAC (Virginia group, lead author Dr. Downes)

In this episode, Nurse Doza breaks down AST. The other liver enzyme marker that makes a huge difference in your liver health. 

What if I told you there might be a way to reduce aging-related muscle loss? Or limit the damage to a heart after a heart attack? Recent research published in Frontiers in Pharmacology has uncovered some unexpected uses for acetaminophen, the common ingredient found in over 400 medications in the US. It turns out that the common ingredient in Tylenol and Excedrin may do more than just relieve pain and reduce fever. In this week's episode, we'll be diving into the fascinating world of off-label uses for acetaminophen. Now this is all very early days - with small sample sizes and very restrictive studies, but an interesting exploration nonetheless. We're diving deep into the research for a nerdy episode you don't want to miss! You'll learn: The surprising potential benefits of acetaminophen Including how it can slow age-related muscle loss and boost muscle growth in older adults with exercise And why a small dose may even have a Neuroprotective effect when it comes to Alzheimer's All the links: Acetaminophen: beyond pain and Fever-relieving. Front Pharmacol. 2011 Influence of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older adults. Am J Physiol Regul Integr Comp Physiol. 2011. How Does Acetaminophen Work? Researchers Still Aren't Sure Join me for the Movement Mavens Retreat! www.aewellness.com/retreat/ 30 days to more strength + flexibility with the Mobility Mastery Toolkit www.aewellness.com/podcast - Show notes, links and more. Come hang out with me on Instagram @hollaformala TikTok @ aewellness Bodywork Starter Guide - learn the 6 places you need to roll right now for quick relief, plus the reason why what you've tried so far has only given you a temporary fix. Download the guide for free now at www.aewellness.com/bodywork 818-396-6501 is the Body Nerd Hotline - how do you build consistency and/or where are you getting stuck? Drop me a line and let me know your body nerd hacks - you might just hear your voice on a future episode! Today's episode is brought to you by Mobility Mastery Toolkit. Forget icing and stretching - and get a simple program you can do on your own that actually works. The Toolkit includes 30-days of exercises so you know exactly what to do to improve the mobility of your hips, lower back, feet, neck and shoulders. With video demos and a full-body mobility workout calendar, you're just 15-mins a day from feeling stronger and more flexible. Get $20 off when you use the code MASTERY at www.mobilitytoolkit.co 

DYK? Acetaminophen is the leading cause of liver transplants in the United States and the United Kingdom (where it is known as paracetamol) and the second largest cause of liver transplants worldwide.In today's episode, we speak with Karen Smith, founder of Catie's Cause, a 501c3 public charity, founded after the tragic loss of her daughter, Catie. Its mission is to build awareness and combat heartache with a goal to educate about the safe use of acetaminophen and share wellness opportunities that lead to less use of over-the-counter pain medications. In the Adjusted Reality podcast, well-known athletes, celebrities, actors, chiropractors, influencers in the wellness industry, and other podcasters will talk with host Dr. Sherry McAllister, president, F4CP, about their experiences with health and wellness. As a special gift for listening today visit f4cp.org/health to get a copy of our mind, body, spirit eBook which focuses on many ways to optimize your health and the ones you love without the use of drugs or surgery. Follow Adjusted Reality on Instagram. Find A Doctor of Chiropractic Near You.Donate to Support the Chiropractic Profession Through Education.

Nearly all pain relievers on the market use the phrase “for fast, temporary relief.” Aspirin, Ibuprofen, Acetaminophen – they'll give a little relief, for a little while. But when it comes to forgiveness of our sin, we're more interest in “immediate, everlasting relief” from our guilt and guile. Today on A NEW BEGINNING, as Pastor Greg Laurie takes us to the story of the first Passover, we'll see God provided a solution for sin that forever paid the price that had to be paid.  Listen on harvest.org --- Learn more and subscribe to Harvest updates at harvest.org . A New Beginning is the daily half-hour program hosted by Greg Laurie, pastor of Harvest Christian Fellowship in Southern California. For over 30 years, Pastor Greg and Harvest Ministries have endeavored to know God and make Him known through media and large-scale evangelism. This podcast is supported by the generosity of our Harvest Partners.Support the show: https://harvest.org/supportSee omnystudio.com/listener for privacy information.

Nearly all pain relievers on the market use the phrase “for fast, temporary relief.” Aspirin, Ibuprofen, Acetaminophen – they'll give a little relief, for a little while. But when it comes to forgiveness of our sin, we're more interest in “immediate, everlasting relief” from our guilt and guile. Today on A NEW BEGINNING, as Pastor Greg Laurie takes us to the story of the first Passover, we'll see God provided a solution for sin that forever paid the price that had to be paid.  Listen on harvest.org --- Learn more and subscribe to Harvest updates at harvest.org . A New Beginning is the daily half-hour program hosted by Greg Laurie, pastor of Harvest Christian Fellowship in Southern California. For over 30 years, Pastor Greg and Harvest Ministries have endeavored to know God and make Him known through media and large-scale evangelism. This podcast is supported by the generosity of our Harvest Partners.Support the show: https://harvest.org/supportSee omnystudio.com/listener for privacy information.

In this episode of the Liver Series, will discuss acetaminophen toxicity. Which is a common over-the-counter- pain reliever and fever reducer. However, it can be toxic to the liver if taken in high doses or in combination with other medications that can damage the liver. Join Dr. Niket Sonpal as he discusses the symptoms of acetaminophen toxicity, which can include nausea, vomiting, abdominal pain and dark urine. And we will go over treatment that will help your patient. August 28, 2023 — Do you work in primary care medicine? Primary Care Medicine Essentials is our brand new program specifically designed for primary care providers to increase their core medical knowledge & improve patient flow optimization. Learn more here: Primary Care Essentials —

This episode is a a high yield "just the facts" break down of the recently released "Management of Acetaminophen Poisoning in the US and Canada Consensus Statement" from the American Academy of Clinical Toxicology, American College of Medical Toxicology, Americans Poisons Centers, and the Canadian Association of Poison Centers. Listen to be informed on the most recent treatment recommendations. This was released alongside a full interview with the consensus statement corresponding author Dr. Richard Dart MD, PhD. Be sure to check out the full interview to hear it straight from the source! (link in show notes).Link to the guidelines:Full interview with consensus statement author Dr. Richard Darthttps://jamanetwork.com/journals/jamanetworkopen/fullarticle/2808062Definitions made by the guidelineAcute ingestion>7.5 g in 24 h per Rummack Matthew initial studies10 g/d or 200 mg/kg/day in 48 hHigh risk ingestionReported dose >30 grams OR[APAP] 2 x Rummack-Matthew nomogram treatment lineNAC stopping criteriaAPAP4 g x >48 hours) AND signs of APAP toxicity (vomiting, RUQ abd pain, AMS)Treat if APAP >20 ug/ml OR AST/ALT elevatedAcuteNon-detectable [APAP] between 2 and 4 hours excludes ingestionGive SDAC w/in 4 hours (something I've been a proponent of since ATOM2)Start treatment with NAC if unable to plot on nomogram by 8 hoursNAC dose“Higher dose” NAC (undefined) for high risk ingestionMinimum NAC regimen should include 300 mg/kg orally or within 20-24 hoursCAP NAC dose at 100 kg (this was known with PO, but IV there was always some question since it delivers less overall)Unique scenariosLine crossersAPAP with anticholinergic or opioidIf 1st  concentration below treatment line repeat in 4-6 hoursAPAP Extended releaseIf 1st  concentration below treatment line @ 4-12 hours, repeat in 4-6 hoursDialysis-Dialyze If APAP >900 w/ AMS or acidosis.NAC IV rate during HD 12.5 mg/kg/hr minimum. No dose change for PO (not new but good reminders)Consult liver transplant for rapid AST/ALT inc w/ coagulopathy, AMS, or mulistytem organ failureThe addition of fomepizole to acetylcysteine in the treatment of serious acetaminophen ingestions has been proposed. The panel concluded that the data available did not support a standard recommendation. As for any complicated or serious acetaminophen poisoning, a PC or clinical toxicologist should be consulted.

Mini episode- High-yield over view of Management of Acetaminophen Poisoning in the US and Canada Consensus Statement In this Ryan sits down with Dr. Richard Dart MD, PhD. He is the lead author of the recently released "Management of Acetaminophen Poisoning in the US and Canada Consensus Statement" from the American Academy of Clinical Toxicology, American College of Medical Toxicology, Americans Poisons Centers, and the Canadian Association of Poison Centers. Listen to be informed on the most recent treatment recommendations.  They dive in to the definitions established by the guideline and notable treatment recommendations, dissecting the ratinonale for each desiscion point and how to apply the guidelines. A mini episode was released along side this episode that is a high yield review of major treatment recommendations and definitions estabilished by the consensus statement.  Links :Mini episode- High-yield over view of Management of Acetaminophen Poisoning in the US and Canada Consensus Statement Guidelines https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2808062Definitions made by the guidelineAcute ingestionAny overdose taken with 24 hours periodOverdose "dose" not defined>7.5 g in 24 h was criteria for Rumack Matthew nomogramConsensus statementAdult overdose at 10g/d or 200 mg/kg/d in 48 hours) AND signs of APAP toxicity (vomiting, RUQ abd pain, AMS)Treat if APAP >20 ug/ml OR AST/ALT elevatedAcuteNon-detectable [APAP] between 2 and 4 hours excludes ingestionGive SDAC w/in 4 hours (something I've been a proponent of since ATOM2)TreatStart treatment with NAC if unable to plot on nomogram by 8 hoursNAC dose“Higher dose” NAC (undefined) for high risk ingestionMinimum NAC regimen should include 300 mg/kg orally or within 20-24 hoursCAP NAC dose at 100 kg (this was known with PO, but IV there was always some question since it delivers less overall)Unique scenariosLine crossersAPAP with anticholinergic or opioidIf 1st  concentration below treatment line repeat in 4-6 hoursAPAP Extended releaseIf 1st  concentration below treatment line @ 4-12 hours, repeat in 4-6 hoursDialysis-Dialyze If APAP >900 w/ AMS or acidosis.NAC IV rate during HD 12.5 mg/kg/hr minimum. No dose change for PO (not new but good reminders)Consult liver transplant for rapid AST/ALT inc w/ coagulopathy, AMS, or mulistytem organ failureThe addition of fomepizole to acetylcysteine in the treatment of serious acetaminophen ingestions has been proposed. The panel concluded that the data available did not support a standard recommendation. As for any complicated or serious acetaminophen poisoning, a PC or clinical toxicologist should be consulted.

It's safe to assume that the vast majority of you have a bottle or blister pack of acetaminophen/paracetamol/Tylenol/Panadol in your home medicine cabinet, and an even vaster majority of you have taken the medicine at some point in your life. After all, acetaminophen/paracetamol is one of the most, if not the most, widely used medications worldwide. Despite its near ubiquity, many unanswered questions remain. How does it actually work? Should safe dosage guidelines be revisited? Why on earth does it have multiple names? And finally, who was responsible for the Tylenol murders in 1982? In this jam-packed episode, we do our best to make sense of the mysteries surrounding this drug, weaving our way from the pharmaceutical nitty gritty of acetaminophen/paracetamol to the bizarre story of its discovery, from the horrific crimes that shocked a nation and revolutionized consumer safety standards to the ongoing discussions of whether we're under- or overestimating how safe this medication actually is.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.